Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Rimini · SciRah

Researcher profile · Semantic Scholar

M. Rimini

Share profile

M. Rimini — researcher profile on SciRah

h-index: 23
Works: 139
Citations: 1,780

Most-cited papers

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
M. Rimini, L. Rimassa, K. Ueshima, V. Burgio +73 more
2022ESMO Open119 citations Open access
Semantic Scholar
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
M. Rimini, L. Fornaro, S. Lonardi, M. Niger +36 more
2023Liver international (Print)102 citations Open access
Semantic Scholar
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Qing-He Zeng, Christophe Klein, Stefano Caruso, P. Maille +41 more
2023The Lancet Oncology90 citations Open access
Semantic Scholar
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
M. Rimini, L. Fornaro, M. Rizzato, L. Antonuzzo +57 more
2024European Journal of Cancer58 citations Open access
Semantic Scholar
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
M. Persano, M. Rimini, T. Tada, G. Suda +75 more
2023European Journal of Cancer54 citations Open access
Semantic Scholar
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
M. Rimini, M. Persano, T. Tada, G. Suda +64 more
2023Journal of Cancer Research and Clinical Oncology39 citations Open access
Semantic Scholar
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
A. Casadei-Gardini, M. Rimini, M. Kudo, S. Shimose +25 more
2022Liver Cancer36 citations Open access
Semantic Scholar
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
M. Persano, M. Rimini, T. Tada, G. Suda +76 more
2022Journal of Cancer Research and Clinical Oncology28 citations Open access
Semantic Scholar
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
M. Persano, M. Rimini, T. Tada, G. Suda +68 more
2023Oncology26 citations Open access
Semantic Scholar
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
F. Rossari, T. Tada, G. Suda, S. Shimose +70 more
2024Liver Cancer25 citations Open access
Semantic Scholar
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
M. Rimini, G. Masi, S. Lonardi, F. Nichetti +45 more
2024Targeted oncology25 citations Open access
Semantic Scholar
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
A. Parisi, B. Delaunay, G. Pinterpe, A. Hollebecque +41 more
2024European Journal of Cancer25 citations Open access
Semantic Scholar
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
M. Rimini, C. Fabregat-Franco, V. Burgio, S. Lonardi +21 more
2022Scientific Reports22 citations Open access
Semantic Scholar
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
M. Rimini, V. Burgio, L. Antonuzzo, L. Rimassa +14 more
2023Therapeutic Advances in Medical Oncology21 citations Open access
Semantic Scholar
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
M. Rimini, M. Persano, T. Tada, G. Suda +66 more
2023Targeted oncology21 citations
Semantic Scholar
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
M. Rimini, T. Macarulla, V. Burgio, S. Lonardi +23 more
2022European Journal of Cancer20 citations Open access
Semantic Scholar
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.
M. Rimini, A. Casadei-Gardini, M. Persano, T. Tada +15 more
2023Journal of Clinical Oncology18 citations Open access
Semantic Scholar
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation
C. Bosi, M. Rimini, A. Casadei-Gardini, Giorgio Ercolani
2023Expert Review of Anticancer Therapy16 citations
Semantic Scholar
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
M. Iavarone, E. Alimenti, T. Tada, S. Shimose +41 more
2023Liver Cancer15 citations Open access
Semantic Scholar
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients
M. Rimini, C. Fabregat-Franco, M. Persano, V. Burgio +22 more
2023Targeted oncology14 citations
Semantic Scholar
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
M. Rimini, L. Fornaro, M. Ikeda, O. Abidoye +74 more
2025Liver international (Print)13 citations Open access
Semantic Scholar
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
T. Aparicio, J. Henriques, M. Svrcek, A. Zaanan +17 more
2024British Journal of Cancer13 citations Open access
Semantic Scholar
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
M. Persano, A. Casadei-Gardini, T. Tada, G. Suda +71 more
2024Oncology13 citations
Semantic Scholar
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
M. Rimini, Wonseok Kang, V. Burgio, M. Persano +34 more
2022Hepatology Research13 citations Open access
Semantic Scholar
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Federica Lo Prinzi, F. Salani, M. Rimini, M. Rizzato +62 more
2024The Oncologist12 citations Open access
Semantic Scholar
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
F. Rossari, T. Tada, G. Suda, S. Shimose +69 more
2023International Journal of Cancer12 citations Open access
Semantic Scholar
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index
M. Persano, M. Rimini, F. Salani, F. L. Prinzi +69 more
2025Liver international (Print)11 citations Open access
Semantic Scholar
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
M. Rimini, Eleonora Loi, M. Rizzato, T. Pressiani +25 more
2024Targeted oncology9 citations
Semantic Scholar
Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study
M. Niger, F. Nichetti, A. Casadei-Gardini, M. Rizzato +26 more
2022International Journal of Cancer9 citations Open access
Semantic Scholar
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
M. Persano, M. Rimini, T. Tada, G. Suda +71 more
2024Targeted oncology8 citations Open access
Semantic Scholar
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis.
F. Ratti, R. Marino, F. Pedica, A. Gardini +7 more
2023Surgery8 citations
Semantic Scholar
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
Federica Lo Prinzi, F. Rossari, M. Silletta, S. Camera +7 more
2025Targeted oncology7 citations
Semantic Scholar
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications
Elisabeth Amadeo, F. Rossari, F. Vitiello, V. Burgio +4 more
2023Expert Review of Clinical Pharmacology7 citations
Semantic Scholar
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population.
M. Rimini, L. Fornaro, Federica Lo Prinzi, M. Rizzato +67 more
2025Journal of the National Cancer Institute6 citations Open access
Semantic Scholar
Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study
M. Niger, M. Rimini, F. Castet, Anna Melzer +25 more
2025Liver international (Print)6 citations Open access
Semantic Scholar
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
M. Rimini, B. Stefanini, T. Tada, G. Suda +74 more
2024Liver international (Print)6 citations
Semantic Scholar
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution
M. Rimini, S. Foti, S. Camera, F. Rossari +9 more
2024Oncology6 citations
Semantic Scholar
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index
M. Persano, M. Rimini, T. Tada, G. Suda +16 more
2023Anticancer Research6 citations Open access
Semantic Scholar
The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT
M. Rimini, P. Franco, F. Bertolini, D. B. Berardino +12 more
2022Journal of Gastrointestinal Cancer6 citations Open access
Semantic Scholar
Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy
C. De Carlo, R. Akpınar, B. Durante, T. Pressiani +27 more
2025Liver Cancer5 citations Open access
Semantic Scholar
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
F. L. Prinzi, F. Salani, S. Camera, M. Rizzato +68 more
2025International Journal of Cancer5 citations Open access
Semantic Scholar
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
A. Vitale, Jung Sun Kim, G. Cabibbo, A. Casadei-Gardini +90 more
2025Liver Cancer5 citations Open access
Semantic Scholar
Treatment options for advanced hepatocellular carcinoma: the potential of biologics
F. Rossari, S. Foti, S. Camera, M. Persano +2 more
2024Expert Opinion on Biological Therapy5 citations
Semantic Scholar
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
M. Rimini, M. Montes, Elisabeth Amadeo, F. Vitiello +35 more
2024Scientific Reports5 citations Open access
Semantic Scholar
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?
M. Persano, A. Casadei-Gardini, V. Burgio, M. Scartozzi +2 more
2022Expert Review of Anticancer Therapy5 citations Open access
Semantic Scholar
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
S. Camera, F. Rossari, S. Foti, F. Vitiello +7 more
2025Targeted oncology4 citations
Semantic Scholar
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA).
Virginia Genovesi, F. Salani, M. Rimini, M. Rizzato +22 more
2025Journal of Hepatology4 citations Open access
Semantic Scholar
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
M. Rimini, L. Fornaro, F. L. Prinzi, M. Rizzato +67 more
2025International Journal of Cancer4 citations Open access
Semantic Scholar
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features.
R. Marino, F. Ratti, A. Casadei-Gardini, M. Rimini +3 more
2024European Journal of Surgical Oncology4 citations Open access
Semantic Scholar
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.
A. Casadei-Gardini, M. Rimini, L. Rimassa, V. Burgio +9 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Casadei-Gardini×45
Invite
A. Casadei-Gardini — researcher profile on SciRah
M. Scartozzi×31
Invite
M. Scartozzi — researcher profile on SciRah
M. Persano×27
Invite
M. Persano — researcher profile on SciRah
S. Lonardi×25
Invite
S. Lonardi — researcher profile on SciRah

×24

Invite

C. Vivaldi — researcher profile on SciRah

Invite

L. Rimassa — researcher profile on SciRah

Invite

F. Rossari — researcher profile on SciRah

Invite

S. Cascinu — researcher profile on SciRah

Invite

G. Suda — researcher profile on SciRah

Invite

V. Burgio — researcher profile on SciRah

T. Pressiani×18

Invite

T. Pressiani — researcher profile on SciRah

Invite

M. Rizzato — researcher profile on SciRah